Assessment of the Anti-Thrombogenic Activity of Polyurethane Starch Composites
The increasing morbidity and mortality of patients due to post-surgery complications of coronary artery bypass grafts (CABPG) are related to blood–material interactions. Thus, the characterization of the thrombogenicity of the biomaterial for cardiovascular devices is of particular interest. This re...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Journal of Functional Biomaterials |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-4983/13/4/184 |
| _version_ | 1797457035007098880 |
|---|---|
| author | Jhoan F. Cespedes Said Arévalo-Alquichire Luis E. Diaz Manuel F. Valero |
| author_facet | Jhoan F. Cespedes Said Arévalo-Alquichire Luis E. Diaz Manuel F. Valero |
| author_sort | Jhoan F. Cespedes |
| collection | DOAJ |
| description | The increasing morbidity and mortality of patients due to post-surgery complications of coronary artery bypass grafts (CABPG) are related to blood–material interactions. Thus, the characterization of the thrombogenicity of the biomaterial for cardiovascular devices is of particular interest. This research evaluated the anti-thrombogenic activity of polyurethanes–starch composites. We previously synthesized polyurethane matrices that were obtained from polycaprolactone diol (PCL), polyethylene glycol (PEG), pentaerythritol (PE), and isophorone diisocyanate (IPDI). In addition, potato starch (AL-N) and zwitterionic starch (AL-Z) were added as fillers. The anti-thrombogenic property was characterized by the clot formation time, platelet adhesion, protein absorption, TAT complex levels, and hemolysis. Additionally, we evaluated the cell viability of the endothelial and smooth muscle cells. Statically significant differences among the polyurethane matrices (P1, P2, and P3) were found for protein absorption and the blood clotting time without fillers. The polyurethanes composites with AL-Z presented an improvement in the anti-thrombogenic property. On the other hand, the composites with AL-Z reduced the viability of the endothelial cells and did not significantly affect the AoSCM (except for P1, which increased). These results classify these biomaterials as inert; therefore, they can be used for cardiovascular applications. |
| first_indexed | 2024-03-09T16:16:22Z |
| format | Article |
| id | doaj.art-fabb44099db4401da082193bda669bfc |
| institution | Directory Open Access Journal |
| issn | 2079-4983 |
| language | English |
| last_indexed | 2024-03-09T16:16:22Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Functional Biomaterials |
| spelling | doaj.art-fabb44099db4401da082193bda669bfc2023-11-24T15:49:04ZengMDPI AGJournal of Functional Biomaterials2079-49832022-10-0113418410.3390/jfb13040184Assessment of the Anti-Thrombogenic Activity of Polyurethane Starch CompositesJhoan F. Cespedes0Said Arévalo-Alquichire1Luis E. Diaz2Manuel F. Valero3Energy, Materials and Environmental Group, GEMA, Faculty of Engineering, Universidad de La Sabana, Chía 140013, ColombiaDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, MA 02114, USABioprospecting Research Group, GIBP, Faculty of Engineering, Universidad de La Sabana, Chía 140013, ColombiaEnergy, Materials and Environmental Group, GEMA, Faculty of Engineering, Universidad de La Sabana, Chía 140013, ColombiaThe increasing morbidity and mortality of patients due to post-surgery complications of coronary artery bypass grafts (CABPG) are related to blood–material interactions. Thus, the characterization of the thrombogenicity of the biomaterial for cardiovascular devices is of particular interest. This research evaluated the anti-thrombogenic activity of polyurethanes–starch composites. We previously synthesized polyurethane matrices that were obtained from polycaprolactone diol (PCL), polyethylene glycol (PEG), pentaerythritol (PE), and isophorone diisocyanate (IPDI). In addition, potato starch (AL-N) and zwitterionic starch (AL-Z) were added as fillers. The anti-thrombogenic property was characterized by the clot formation time, platelet adhesion, protein absorption, TAT complex levels, and hemolysis. Additionally, we evaluated the cell viability of the endothelial and smooth muscle cells. Statically significant differences among the polyurethane matrices (P1, P2, and P3) were found for protein absorption and the blood clotting time without fillers. The polyurethanes composites with AL-Z presented an improvement in the anti-thrombogenic property. On the other hand, the composites with AL-Z reduced the viability of the endothelial cells and did not significantly affect the AoSCM (except for P1, which increased). These results classify these biomaterials as inert; therefore, they can be used for cardiovascular applications.https://www.mdpi.com/2079-4983/13/4/184anti-thrombogenic propertypolyurethanes compositespotato starchzwitterionic starchbiomaterialscardiovascular applications |
| spellingShingle | Jhoan F. Cespedes Said Arévalo-Alquichire Luis E. Diaz Manuel F. Valero Assessment of the Anti-Thrombogenic Activity of Polyurethane Starch Composites Journal of Functional Biomaterials anti-thrombogenic property polyurethanes composites potato starch zwitterionic starch biomaterials cardiovascular applications |
| title | Assessment of the Anti-Thrombogenic Activity of Polyurethane Starch Composites |
| title_full | Assessment of the Anti-Thrombogenic Activity of Polyurethane Starch Composites |
| title_fullStr | Assessment of the Anti-Thrombogenic Activity of Polyurethane Starch Composites |
| title_full_unstemmed | Assessment of the Anti-Thrombogenic Activity of Polyurethane Starch Composites |
| title_short | Assessment of the Anti-Thrombogenic Activity of Polyurethane Starch Composites |
| title_sort | assessment of the anti thrombogenic activity of polyurethane starch composites |
| topic | anti-thrombogenic property polyurethanes composites potato starch zwitterionic starch biomaterials cardiovascular applications |
| url | https://www.mdpi.com/2079-4983/13/4/184 |
| work_keys_str_mv | AT jhoanfcespedes assessmentoftheantithrombogenicactivityofpolyurethanestarchcomposites AT saidarevaloalquichire assessmentoftheantithrombogenicactivityofpolyurethanestarchcomposites AT luisediaz assessmentoftheantithrombogenicactivityofpolyurethanestarchcomposites AT manuelfvalero assessmentoftheantithrombogenicactivityofpolyurethanestarchcomposites |